Intensity Therapeutics Inc. (NASDAQ:INTS) Short Interest Update

Intensity Therapeutics Inc. (NASDAQ:INTS) saw a significant growth in short interest during the month of June. As of June 30th, there was short interest totaling 126,421 shares, a growth of 117.2% from the June 15th total of 58,214 shares. Currently, 5.1% of the company’s shares are short sold. Based on an average daily volume of 76,377 shares, the days-to-cover ratio is currently 1.7 days.

Institutional Investors Weigh In On Intensity Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in INTS. Jane Street Group LLC purchased a new stake in Intensity Therapeutics during the fourth quarter valued at approximately $26,000. Corient Private Wealth LLC purchased a new stake in shares of Intensity Therapeutics in the 4th quarter worth $41,000. State Street Corp increased its stake in shares of Intensity Therapeutics by 839.3% in the 4th quarter. State Street Corp now owns 136,200 shares of the company’s stock worth $56,000 after purchasing an additional 121,700 shares in the last quarter. Legacy Advisors LLC bought a new position in Intensity Therapeutics in the 4th quarter worth $63,000. Finally, Mesirow Financial Investment Management Inc. lifted its position in Intensity Therapeutics by 25.5% during the fourth quarter. Mesirow Financial Investment Management Inc. now owns 251,000 shares of the company’s stock valued at $103,000 after purchasing an additional 51,000 shares in the last quarter. Hedge funds and other institutional investors own 3.74% of the company’s stock.

Intensity Therapeutics Stock Performance

INTS stock traded up $0.04 on Wednesday, hitting $4.92. The company had a trading volume of 20,734 shares, compared to its average volume of 46,246. The company has a current ratio of 4.86, a quick ratio of 4.86 and a debt-to-equity ratio of 0.01. Intensity Therapeutics has a 12-month low of $3.51 and a 12-month high of $43.50. The stock has a market cap of $13.27 million, a price-to-earnings ratio of -0.86 and a beta of 2.78. The stock’s 50-day simple moving average is $4.36 and its 200 day simple moving average is $6.45.

Intensity Therapeutics (NASDAQ:INTS) last released its quarterly earnings results on Thursday, May 7th. The company reported ($0.96) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.08) by $0.12. As a group, equities research analysts expect that Intensity Therapeutics will post -2.7 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on INTS shares. Benchmark reissued a “speculative buy” rating on shares of Intensity Therapeutics in a research note on Wednesday, May 20th. Freedom Capital upgraded shares of Intensity Therapeutics from a “hold” rating to a “strong-buy” rating in a report on Monday, March 30th. Wall Street Zen upgraded shares of Intensity Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, April 4th. Finally, Weiss Ratings downgraded shares of Intensity Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday, April 24th. One investment analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $37.50.

Intensity Therapeutics Company Profile

Intensity Therapeutics, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of cancer drugs to treat solid tumors. The company's lead product candidate is INT230-6, which is in Phase 2 clinical trial for the treatment of refractory solid tumors; and pancreatic, colon, bile duct, squamous cell carcinoma, sarcoma, breast, and liver cancers. It has a collaboration agreement with Merck Sharpe & Dohme Corp. to evaluate the combination of INT230-6 and Keytruda in patients with advanced pancreatic, colon, squamous cell, and bile duct malignancies; Bristol-Myers Squibb Company to evaluate the combination of INT230-6 with Yervoy in patients with advanced liver, breast, and sarcoma cancers; and Ottawa Hospital Research Institute and the Ontario Institute of Cancer Research to study INT230-6 in a randomized controlled neoadjuvant phase II study in women with early-stage breast cancer.